Hetero gets DCGI nod to launch Remdesivir for Covid-19 treatment

Hetero will produce and launch the first generic Remdesivir under Covifor brand in India following positive clinical outcomes under a licensing agreement with Gilead Sciences Inc to expand access to Covid-19 treatment in low and middle-income economies.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2V1WVmm
via IFTTT